Iradimed Corp Sees 11% Revenue Growth

By Bobby Samwell • Monday, May 05 15:22 • Permanent Link

Iradimed Corporation, a leader in developing innovative magnetic resonance imaging ("MRI") compatible medical devices, has announced its financial results for the first quarter of 2025. The company reported record revenue of $19.5 million for the first quarter of 2025, marking an 11% increase compared to the same period in 2024.

The GAAP diluted EPS for the first quarter of 2025 was reported at $0.37, representing a 16% increase from the same period in 2024. On a non-GAAP basis, diluted EPS for the first quarter of 2025 was reported at $0.42, reflecting a 17% increase from the same period in 2024.

The company declared a regular quarterly cash dividend of $0.17 per common share for the second quarter of 2025, underscoring its commitment to delivering value to its shareholders.

For the second quarter of 2025, the company expects revenue in the range of $19.7 million to $19.9 million, with GAAP diluted earnings per share projected to be between $0.37 and $0.40, and non-GAAP diluted earnings per share expected to fall within the range of $0.41 to $0.44.

Looking ahead to the full year 2025, Iradimed Corporation reaffirmed its guidance, expecting to report revenue in the range of $78.0 million to $82.0 million, with GAAP diluted earnings per share projected to be between $1.55 and $1.65, and non-GAAP diluted earnings per share expected to fall within the range of $1.71 to $1.81.

The company reported that for the three months ended March 31, 2025, revenue from domestic sales accounted for 82% of the total revenue, compared to 76% for the comparable period of 2024. The gross profit margin remained constant at 76.1% for both the three months ended March 31, 2025, and 2024.

Iradimed Corporation's cash flow from operations for the three months ended March 31, 2025, amounted to $4.3 million, reflecting an increase of 10% compared to the same period in 2024.

The company's financial guidance for the second quarter and full year 2025 excludes stock-based compensation expense, net of tax expense. It expects stock-based compensation expense, net of tax, to be approximately $2.6 million for the full year and $0.6 million for the second quarter of 2025.

As a result of these announcements, the company's shares have moved -1.8% on the market, and are now trading at a price of $52.51. If you want to know more, read the company's complete 8-K report here.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.